Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.
